ADVANCEMENTS IN CANCER RESEARCH AND THERAPEUTICS CONFERENCE – ACRT 2026
March 25–27, 2026 | Boston, USA
We are honored to invite you to the Advancements in Cancer Research and Therapeutics (ACRT) 2026 international conference, taking place from March 25 to 27, 2026, in Boston, Massachusetts—a global hub for biomedical research and pharmaceutical innovation.
ACRT 2026 serves as a dynamic platform for leading minds in oncology, cancer biology, immuno-oncology, molecular diagnostics, translational medicine, and biopharmaceutical development to come together and explore the latest breakthroughs in cancer science and treatment. Read More
This globally significant event will convene a multidisciplinary community of:
- Academic and clinical researchers
- Medical and surgical oncologists
- Biotech and pharmaceutical industry leaders
- Translational scientists and drug development experts
- Regulatory authorities and healthcare policymakers
Conference highlights include:
- Scientific sessions on cancer genomics, precision oncology, and immunotherapy
- Keynote lectures by global leaders in cancer research and drug discovery
- Workshops on translational research, clinical trial design, and regulatory pathways
- Short symposiums on emerging therapeutics, biomarkers, and companion diagnostics
- Dedicated sessions for biotech innovations, AI in oncology, and pharma-academia partnerships
- Robust networking forums and B2B engagement opportunities
Whether your focus is on basic research, clinical oncology, therapeutic development, or industry innovation, ACRT 2026 offers a unique opportunity to stay at the forefront of cancer treatment strategies and collaborative advancement.
Join us in Boston to shape the future of oncology—through discovery, innovation, and global collaboration.
Together, let’s advance the science that saves lives.
Plenaries and Keynotes
Tyler Jacks
MIT, Boston
Rakesh K. Jain
Harvard Medical School and
Massachusetts General Hospital, Boston
Ellen Pure
University of Pennsylvania, PA
A Thomas Look
Dana-Farber Cancer Institute,
Harvard Medical School, MA
Douglas Green
St Jude Children's Research Hospital, TN
Kai Wucherpfennig
Dana-Farber Cancer Institute,
Harvard Medical School, MA
John Quackenbush
Harvard T.H. Chan School of
Public Health, MA
Ying-Chih Chang
AcroCyte Therapeutics Inc., Taiwan
Khalid Shah
Harvard Medical School , MA
XingXing Zang
Albert Einstein College of Medicine, NY
John Bridgeman
CSO, Immunokey Ltd, UK